Interview with Merce Boada, MOPEAD project leader, Founder and Medical Director of Fundació ACE, Institut Català de Neurociències Aplicades
What is MOPEAD, how would you describe the project?
What are the issues MOPEAD tackles and what novelties will be delivered?
What are the benefits to General population?
(Article from lillypad.eu)
What is MOPEAD, who is involved and where is it taking place?
In Alzheimer’s disease (AD), as in other conditions, involving patients is a sure way to improve diagnosis and care. One of the main causes of delayed AD diagnosis is the lack of awareness, in the general population, of cognitive decline. We need to clarify the meaning of cognitive decline and raise awareness of the signs to look out for, so that we can start to diagnose AD earlier.